Radiopharm Theranostics Files 6-K Report
Ticker: RDPTF · Form: 6-K · Filed: Sep 17, 2025 · CIK: 1949257
| Field | Detail |
|---|---|
| Company | Radiopharm Theranostics Ltd (RDPTF) |
| Form Type | 6-K |
| Filed Date | Sep 17, 2025 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: 6-K, foreign-private-issuer, regulatory-filing
TL;DR
Radiopharm Theranostics (RPT) filed a 6-K, confirming its foreign private issuer status and 20-F filing for 2025.
AI Summary
Radiopharm Theranostics Ltd, a pharmaceutical preparations company, filed a Form 6-K on September 17, 2025. The filing is a report of a foreign private issuer for the month of September 2025, indicating it files annual reports under Form 20-F. The company's principal executive office is located in Carlton South, Victoria, Australia.
Why It Matters
This filing provides an update on Radiopharm Theranostics' regulatory status as a foreign private issuer, which is important for investors tracking its compliance and reporting obligations in the U.S.
Risk Assessment
Risk Level: low — This is a routine administrative filing confirming the company's reporting status and location, with no new material financial or operational information.
Key Players & Entities
- Radiopharm Theranostics Ltd (company) — Registrant
- 0001949257 (company) — Central Index Key
- 001-41621 (company) — SEC File Number
- 251318921 (company) — Film Number
- September 2025 (date) — Reporting Period
- 20250917 (date) — Filing Date
FAQ
What type of report is Radiopharm Theranostics Limited filing?
Radiopharm Theranostics Limited is filing a Form 6-K, which is a Report of Foreign Private Issuer.
What is the filing date of this Form 6-K?
The filing date of this Form 6-K is September 17, 2025.
Does Radiopharm Theranostics file annual reports under Form 20-F or 40-F?
Radiopharm Theranostics indicates it files annual reports under cover of Form 20-F.
Where is Radiopharm Theranostics Limited's principal executive office located?
The principal executive office of Radiopharm Theranostics Limited is located at Level 3, 62 Lygon Street, Carlton South, Victoria, 3053, Australia.
Is Radiopharm Theranostics furnishing information under Rule 12g3-2(b)?
No, Radiopharm Theranostics is not furnishing information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934, as indicated by the 'No' checkbox being marked.
Filing Stats: 316 words · 1 min read · ~1 pages · Grade level 19.2 · Accepted 2025-09-17 09:23:31
Filing Documents
- ea0257680-6k_radio.htm (6-K) — 12KB
- ea025768001ex99-1_radio.htm (EX-99.1) — 239KB
- ex99-1_001.jpg (GRAPHIC) — 2KB
- 0001213900-25-088387.txt ( ) — 255KB
From the Filing
OF FOREIGN PRIVATE ISSUER UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of September 2025 Commission File Number: 001-41621 RADIOPHARM THERANOSTICS LIMITED (Name of Registrant) Level 3, 62 Lygon Street, Carlton South, Victoria, 3053, Australia (Address of principal executive office) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F Form 40-F Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934. Yes No If “Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82- RADIOPHARM THERANOSTICS LIMITED EXPLANATORY NOTE Radiopharm Theranostics Limited (the “Company”) published one announcement (the “Public Notice”) to the Australian Securities Exchange on September 17, 2025 titled: - “Corporate Governance Statement and Appendix 4G” A copy of the Public Notice is attached as an exhibit to this report on Form 6-K. This report on Form 6-K (including the exhibit hereto) shall not be deemed to be “filed” for purposes of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) and shall not be incorporated by reference into any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing. 1 EXHIBITS Exhibit Number Description 99.1 Corporate Governance 2 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. RADIOPHARM THERANOSTICS LIMITED Date: September 17, 2025 By: /s/ Phillip Hains Phillip Hains Company Secretary 3